# US 2024/0391928 A1 · Compositions for the treatment of food and chemical addiction and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391928 A1
- Document ID: US20240391928A1
- Status: Published application
- Kind: A1
- Application number: 18/694,167
- Filed: 2022-02-17
- Published: 2024-11-28
- Earliest claimed: 2021-09-22
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Dan Jansen; Juan Jose Marugan; Krisztian Toth; Lawrence Barak; Marc G. Caron; Joshua Gross; David Kim; Tae Gyun Yang
- Web page: https://patentgrep.com/patent/US20240391928A1

## CPC

- C07D 491/052: the oxygen-containing ring being six-membered
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/30: for treating abuse or dependence
- C07D 311/24: with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating health conditions can include administering an effective amount of at least one of the compounds or compositions disclosed herein to a subject having or suspected of having an imbalance in brain dopamine homeostasis.

## Claims

### Claim 1

A compound of Formula (I), analogs, isomers, pharmaceutically acceptable salts, and prodrugs thereof or a pharmaceutically acceptable salt thereof:
wherein R1, R2, R3, and R4 are independently selected from a group consisting of H, NO2, CN, CHO, F, Cl, Br, I, CF3, unsubstituted C1-C6 alkyl, substituted alkyl, COR12, CO2H, CO2R13, CONH2, CONHR14, and CONR15R16;
R5 is selected from a group consisting of OH, OR17, NH2, NHR18 NR19R20 NHCOR21, NHCO2R22 and heterocyclic;
R6 is H or an unsubstituted C1-C6 alkyl,
Ar is
R7, R8, R9, R10, and R11 are independently H, F, Cl, Br, I, CF3, CN, OH, OR23, NH2, NHR24 NR25R26, NHCOR2, NHCO2R28, unsubstituted C1-C6 alkyl, substituted C1-C6 alkyl, unsubstituted C2-C6 cycloalkyl, substituted C2-C6 cycloalkyl, unsubstituted C1-C6 alkenyl, substituted C1-C6 alkenyl, unsubstituted C1-C6 alkynyl, substituted C1-C6 alkynyl, unsubstituted phenyl, substituted phenyl, R7 and R8 may be taken together to form an unsubstituted C1-C6 alkyl, or a substituted C1-C6 alkyl, R8 and R9 may be taken together to form an unsubstituted C1-C6 alkyl, or a substituted C1-C6 alkyl, R9 and R10 may be taken together to form an unsubstituted C1-C6 alkyl, or a substituted C1-C6 alkyl, R10 and R11 may be taken together to form an unsubstituted C1-C6 alkyl, or a substituted C1-C6 alkyl;
R12, R13, R14, R15, R16, R17, R18, R19, R20R21, R22, R23, R24, R25, R26, R27 and R28 are independently selected from a group consisting of H, unsubstituted C1-C6 alkyl, substituted C1-C6 alkyl, unsubstituted phenyl, substituted phenyl, heterocyclic, R15 and R16 may be taken together to form an unsubstituted C1-C6 alkyl or a substituted C1-C6 alkyl, and R19 and R20 may be taken together to form an unsubstituted C1-C6 alkyl or a substituted C1-C6 alkyl; and
n is an integer from 1 to 6;
wherein an unsubstituted alkyl, cycloalkyl, or phenyl group comprises all carbon atoms, and a substituted alkyl, cycloalkyl, or aryl group comprises at least one nitrogen atom, oxygen atom, halogen atom, or a combination thereof for at least one carbon atom.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1, R2, R3, and R4 are independently selected from a group consisting of H, N02, CN, CHO, F, Cl, Br, I, CF3, unsubstituted C1-C6 alkyl, substituted C1-C6 alkyl, COR12, CO2H, CO2R13, CONH2, CONHR14, and CONR15R16;
R5 is selected from a group consisting of OH, OR17, NH2, NHR18, NR19R20, NHCOR21, and NHCO2R22;
R6 is H or an unsubstituted C1-C6 alkyl;
Ar is
R7, R8, R9, R10, and R11 are independently H, F, Cl, Br, I, CF3, CN, OH, OR23, unsubstituted C1-C4 alkyl, substituted C1-C4 alkyl, unsubstituted phenyl, or substituted phenyl, R7 and R8 may be taken together to form an unsubstituted C1-C4 alkyl, or a substituted C1-C4 alkyl, R8 and R9 may be taken together to form an unsubstituted C1-C4 alkyl, or a substituted C1-C4 alkyl, R9 and R10 may be taken together to form an unsubstituted C1-C4 alkyl, or a substituted C1-C4 alkyl, R10 and R11 may be taken together to form an unsubstituted C1-C4 alkyl, or a substituted C1-C4 alkyl;
R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, and R23, are independently selected from a group consisting of H, C1-C4 alkyl, unsubstituted phenyl, substituted phenyl, heterocycle, and R19 and R20 may be taken together to form an unsubstituted C1-C6 alkyl or a substituted C1-C6 alkyl; and
n is an integer from 1 to 4;
wherein an unsubstituted alkyl, cycloalkyl, or phenyl group comprises all carbon atoms, and a substituted alkyl, cycloalkyl, or aryl group comprises at least one nitrogen atom, oxygen atom, halogen atom, or a combination thereof for at least one carbon atom.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R1, R2, R3, and R4 are independently selected from a group consisting of H, F, Cl, Br, I, CF3, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, and C(CH3)3;
R5 is selected from a group consisting of NHCH3, N(CH3)2, NHCH2CH3, N(CH2CH3)2, NHCH2CH2CH3, N(CH2CH2CH3)2, NHCH(CH3)2, N(CH(CH3)2)2, NCH3Ph, NCH2CH3Ph, NCH3CH(CH3)2, NH(C(CH3)3, pyridine, pyrazole, pyridazine, and pyrimidine;
R is H or CH3;
Ar is
R7, R8, R9, R10, and R11 are independently selected from a group consisting of H, F, Cl, Br, I, CF3, CN, OH, OCH3, OCH2CH3, OPh, CH3, CH and n is an integer from 1 to 4.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1, R3, R4, and R6 are H; R2 is Cl; R5 is N(CH3)2;
Ar is
R7, R8, and R11 are H; R8 and R9 are OCH3; and n=3 as shown in the compound comprising Formula (III):

### Claim at position 5

-8. (canceled)

### Claim 9 (depends on 1)

The compound according to claim 1, wherein the compound comprises agonistic activity toward growth hormone secretagogue receptor 1a (GHSR1a).

### Claim 10 (depends on 1)

The compound according to claim 1, wherein the compound comprises a biased agonist of GHSR1a.

### Claim 11 (depends on 10)

The compound according to claim 10, wherein the compound comprises a G protein-bias.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein the compound comprises a G protein-bias to one or more G alpha subunits.

### Claim 13 (depends on 12)

The compound according to claim 12, wherein the one or more G alpha subunits comprises Gαs, Gαolf, Gαi1, Gαi2, Gαi3, GαoA, GαoB, Gαz, Gαq, Gα11, Gα14, Gα15, Gα12, Gα13, or any combination thereof.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein the compound comprises a G protein-bias to Gαq.

### Claim 15 (depends on 1)

The compound according to claim 1, wherein the compound does not compete with ghrelin peptide for binding to the GHSR1a.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 17 (depends on 1, 16)

A method for treating a subject having a health condition, comprising administering to the subject having a health condition, the compound according to claim 1 or the pharmaceutical composition according to claim 16.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the subject having a health condition comprises an imbalance in brain dopamine homeostasis.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the imbalance in brain dopamine homeostasis comprises Parkinson's disease, attention deficit hyperactivity disorder, Tourette syndrome, schizophrenia, bipolar disorder, Alzheimer's Disease, addiction, eating disorder, or any combination thereof.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the imbalance in brain dopamine homeostasis comprises a neurological disorder associated with involuntary motor movements.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the neurological disorder associated with involuntary motor movements is Parkinson's disease.

### Claim 22 (depends on 18)

The method according to claim 18, wherein the imbalance in brain dopamine homeostasis comprises an addition to a drug, alcohol, food, or any combination thereof.

### Claim 23 (depends on 18)

The method according to claim 18, wherein the imbalance in brain dopamine homeostasis comprises an eating disorder.

### Claim 24 (depends on 1, 16, 17)

The method according to claim 17, wherein the compound according to claim 1 or the pharmaceutical composition according to claim 16 is administered to the subject systemically, topically, subcutaneously, or by direct administration into a brain tissue.

### Claim 25 (depends on 1, 16, 24)

The method according to claim 24, wherein the compound according to claim 1 or the pharmaceutical composition according to claim 16 is administered to the subject orally.

### Claim 26 (depends on 1, 16, 25)

The method according to claim 25, wherein the compound according to claim 1 or the pharmaceutical composition according to claim 16 is administered to the subject orally at a concentration ranging from about 0.5 mg/kg to about 50 mg/kg.

### Claim 27 (depends on 1, 16, 26)

The method according to claim 26, wherein the compound according to claim 1 or the pharmaceutical composition according to claim 16 is administered to the subject orally, wherein the compound according to claim 1 comprises an oral bioavailability of 1% to 15%.

### Claim 28 (depends on 1, 16, 24)

The method according to claim 24, wherein the compound according to claim 1 or the pharmaceutical composition according to claim 16 is administered to the subject intraperitoneally.

### Claim 29 (depends on 1, 16, 28)

The method according to claim 28, wherein the compound according to claim 1 or the pharmaceutical composition according to claim 16 is administered to the subject intraperitoneally at a concentration ranging from about 0.5 mg/kg to about 50 mg/kg.

### Claim 30 (depends on 1, 16, 29)

The method according to claim 29, wherein the compound according to claim 1 or the pharmaceutical composition according to claim 16 is administered to the subject intraperitoneally, wherein the compound according to claim 1 comprises an IP bioavailability of 10% to 35%.

### Claim 31 (depends on 1, 16)

A kit comprising the compound according to claim 1 or the pharmaceutical composition according to claim 16, and at least one container.

### Claim 32 (depends on 31)

The kit according to claim 31, wherein the kit is of use to treat a health condition in a subject having or suspected of having an imbalance in brain dopamine homeostasis.
